Boston Biotech Clinical Research
  • Home
    • SCIO Path to Approval
  • Early Clinical Research
    • Strategy and TPP
    • Translational Medicine and Epigenetics
    • Biologics, Cell and Gene Therapy
    • Real World Evidence
    • Repurposing
  • Orphan Drug Solutions
    • Biomarkers and Surrogate Endpoints
    • Regulatory Affairs FDA and EMA
    • Medical Affairs and Clinical Research
    • Due Diligence
    • Trial Management & Trial Rescue
  • People
    • Senior Advisors
      • Candida Fratazzi
      • Claudio Carini
      • Federico Goodsaid
    • Our Clients
    • Our Collaborators
    • Testimonials
  • Resources
    • BBCR Voice
    • Case Studies
    • Published Studies
    • Conferences & Presentations
    • Job Opportunities
    • Contact Info
Select Page

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Categories

  • Biomarkers & Surrogate Endpoints
  • Company News
  • Drug Development
  • Due Diligence
  • Early Clinical Development
  • Industry News
  • Medical Affairs and Clinical Research
  • Miscellaneous
  • Orphan Diseases
  • Pre-IND
  • Precision Medicine
  • Rare Disease
  • Real World Evidence
  • Regulatory
  • Regulatory Affairs
  • Strategy and TPP
  • Translation Medicine and Epigenetics
  • Trial Management
  • Trial Rescue

Recent Posts

  • Partnering with BBCR Consulting means gaining the support of a specialized team committed to making the clinical trial process more efficient.
  • Who is BBCR and how do we help pharmaceutical innovators in the specialized rare diseases and orphan drug industries? We invite you to learn more at bbcrconsulting.com.
  • Accelerate Drug Development with Biomarker Strategy in Orphan Diseases and Precision Medicine
  • At BBCR, our team of seasoned experts is dedicated to helping clients navigate the intricate landscape of rare genetic conditions and unsolved diseases. We work hand in hand with product developers to create the most effective strategies for bringing innovative treatments to market.
  • Our experienced CRO Management and Drug development team identify study remediation strategies and provide a resource for any Study Rescue. We invite you to reach out to learn more – visit bbcrconsulting.com.

RSS Nasdaq Globe Newswire

  • Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules September 15, 2025
  • Global Main Automation Contractor (MAC) Market Size/Share Worth USD 10.39 Billion by 2034 at a 7.49% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) September 15, 2025
  • ROTH Further Expands its Equity Research Team with the Addition of Adam Walsh, MD and Nick Pope September 15, 2025
  • aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis September 15, 2025
PRIVACY POLICY
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn

©2025 Boston Biotech Clinical Research. All Rights Reserved.   |   Web Design by Nisse Designs